Lutetium Lu-177 vipivotide tetraxetan

What it's for

Lutetium Lu-177 vipivotide tetraxetan is a radioligand that binds prostate-specific membrane antigen. Treats PSMA-positive metastatic castration-resistant prostate cancer after androgen-receptors (lock-and-key landing spots on cells) pathway inhibition and taxane therapy as labeled.

What it does for the body

Treats PSMA-positive metastatic castration-resistant prostate cancer after androgen-receptors (lock-and-key landing spots on cells) pathway inhibition and taxane therapy as labeled. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.

What it targets

PSMA binding delivers beta radiation to PSMA-expressing prostate cancer cells and nearby microenvironment. Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.

Research context

Bottom line for readers: Lutetium Lu-177 vipivotide tetraxetan has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.

Studied for (literature interest)

• Sexual research interest (educational tag)

Cautions (educational)

• Educational only — not medical advice.
• DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.

Citations / starters

• FDA search: Lutetium Lu-177 vipivotide tetraxetan — FDA.gov search
• ClinicalTrials.gov search: Lutetium Lu-177 vipivotide tetraxetan — U.S. clinical trials registry
• Drugs@FDA search: Lutetium Lu-177 vipivotide tetraxetan — FDA drug database (if approved)
• PubMed search: Lutetium Lu-177 vipivotide tetraxetan — NCBI PubMed
• PubMed Central search: Lutetium Lu-177 vipivotide tetraxetan — NCBI PMC

Reference

No ref on file.